Сравнение

Maridebart Cafraglutide vs. Survodutide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

2179963-22-7

Молекулярная масса

нет данных

4727 g/mol

Период полувыведения

нет данных

168 h

Последовательность

нет данных

modifiziertes 29-Aminosäuren-Peptid mit Fettsäureseitenkette

Механизм действия

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Survodutide

Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Maridebart Cafraglutide	Survodutide
Германия	Не одобрено	Не одобрено
JP	—	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Maridebart Cafraglutide

Полная запись →

Survodutide

Полная запись →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Survodutide?: Maridebart Cafraglutide is classified as "Метаболизм", while Survodutide is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or Survodutide?: The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and Survodutide in Germany and the United States?: Германия: Maridebart Cafraglutide — Не одобрено, Survodutide — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Survodutide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

Survodutide

Германия

Не одобрено

—

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Survodutide?

Maridebart Cafraglutide is classified as "Метаболизм", while Survodutide is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or Survodutide?

The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and Survodutide in Germany and the United States?

Германия: Maridebart Cafraglutide — Не одобрено, Survodutide — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Survodutide — Не одобрено. These are factual summaries with source and review date on the individual pages.